Societal preference values for advanced melanoma health states in the United Kingdom and Australia

被引：60

作者：

Beusterien, K. M. ^{[1
]}

Szabo, S. M. ^{[2
]}

Kotapati, S. ^{[3
]}

Mukherjee, J. ^{[3
]}

Hoos, A. ^{[3
]}

Hersey, P.

Middleton, M. R. ^{[4
]}

Levy, A. R. ^{[2
,5
]}

机构：

[1] Oxford Outcomes Inc, Bethesda, MD 20814 USA

[2] Oxford Outcomes Ltd, Vancouver, BC V6B 1P1, Canada

[3] Bristol Myers Squibb Co, Wallingford, CT 06492 USA

[4] Churchill Hosp, Canc Res UK Med Oncol Unit, Oxford OX3 7LJ, England

[5] Univ British Columbia, Dept Hlth Care & Epidemiol, Vancouver, BC V6T 1Z4, Canada

来源：

BRITISH JOURNAL OF CANCER | 2009年 / 101卷 / 03期

关键词：

melanoma; utility; standard gamble; preferences; QUALITY-OF-LIFE; ADJUVANT INTERFERON-ALPHA-2B; METASTATIC MELANOMA; CUTANEOUS MELANOMA; COST-EFFECTIVENESS; UTILITIES; SCORES; ALPHA;

D O I：

10.1038/sj.bjc.6605187

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND: No studies measure preference-based utilities in advanced melanoma that capture both intended clinical response and unintended toxicities associated with treatment. METHODS: Using standard gamble, utilities were elicited from 140 respondents in the United Kingdom and Australia for 13 health states. RESULTS: Preferences decreased with reduced treatment responsiveness and with increasing toxicity. CONCLUSION: These general population utilities can be incorporated into treatment-specific cost-effectiveness evaluations. British Journal of Cancer (2009) 101, 387-389. doi:10.1038sj.bjc.6605187 www.bjcancer.com Published online 14 July 2009 (C) 2009 Cancer Research UK

引用

页码：387 / 389

页数：3

共 24 条

[1]

[Anonymous], England and Wales Census 1901 FamilySearch database

[2]

[Anonymous], WHO PUBL

[3]

[Anonymous], 2006, Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0

[4]

*AUSTR BUR STAT, 2007, 2006 QUICKSTATS AUST